Cargando…
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular driver...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310231/ https://www.ncbi.nlm.nih.gov/pubmed/35898967 http://dx.doi.org/10.1177/17588359221111705 |
_version_ | 1784753344531660800 |
---|---|
author | Yu, Irene S. Aubin, Francine Goodwin, Rachel Loree, Jonathan M. Mather, Cheryl Sheffield, Brandon S. Snow, Stephanie Gill, Sharlene |
author_facet | Yu, Irene S. Aubin, Francine Goodwin, Rachel Loree, Jonathan M. Mather, Cheryl Sheffield, Brandon S. Snow, Stephanie Gill, Sharlene |
author_sort | Yu, Irene S. |
collection | PubMed |
description | The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular drivers of colorectal cancer not only aided the development of novel targeted therapies but led to the discovery of tumor mutations which act as predictive biomarkers for therapeutic response. Mutational status of the KRAS gene became the first genomic biomarker to be established as part of standard of care molecular testing, where KRAS mutations within exons 2, 3, and 4 predict a lack of response to anti- epidermal growth factor receptor therapies. Since then, several other biomarkers have become relevant to inform mCRC treatment; however, there are no published Canadian guidelines which reflect the current standards for biomarker testing. This guideline was developed by a pan-Canadian advisory group to provide contemporary, evidence-based recommendations on the minimum acceptable standards for biomarker testing in mCRC, and to describe additional biomarkers for consideration. |
format | Online Article Text |
id | pubmed-9310231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-93102312022-07-26 Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline Yu, Irene S. Aubin, Francine Goodwin, Rachel Loree, Jonathan M. Mather, Cheryl Sheffield, Brandon S. Snow, Stephanie Gill, Sharlene Ther Adv Med Oncol Review The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular drivers of colorectal cancer not only aided the development of novel targeted therapies but led to the discovery of tumor mutations which act as predictive biomarkers for therapeutic response. Mutational status of the KRAS gene became the first genomic biomarker to be established as part of standard of care molecular testing, where KRAS mutations within exons 2, 3, and 4 predict a lack of response to anti- epidermal growth factor receptor therapies. Since then, several other biomarkers have become relevant to inform mCRC treatment; however, there are no published Canadian guidelines which reflect the current standards for biomarker testing. This guideline was developed by a pan-Canadian advisory group to provide contemporary, evidence-based recommendations on the minimum acceptable standards for biomarker testing in mCRC, and to describe additional biomarkers for consideration. SAGE Publications 2022-07-20 /pmc/articles/PMC9310231/ /pubmed/35898967 http://dx.doi.org/10.1177/17588359221111705 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Yu, Irene S. Aubin, Francine Goodwin, Rachel Loree, Jonathan M. Mather, Cheryl Sheffield, Brandon S. Snow, Stephanie Gill, Sharlene Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline |
title | Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian
Consensus Practice Guideline |
title_full | Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian
Consensus Practice Guideline |
title_fullStr | Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian
Consensus Practice Guideline |
title_full_unstemmed | Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian
Consensus Practice Guideline |
title_short | Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian
Consensus Practice Guideline |
title_sort | tumor biomarker testing for metastatic colorectal cancer: a canadian
consensus practice guideline |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310231/ https://www.ncbi.nlm.nih.gov/pubmed/35898967 http://dx.doi.org/10.1177/17588359221111705 |
work_keys_str_mv | AT yuirenes tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT aubinfrancine tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT goodwinrachel tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT loreejonathanm tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT mathercheryl tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT sheffieldbrandons tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT snowstephanie tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline AT gillsharlene tumorbiomarkertestingformetastaticcolorectalcanceracanadianconsensuspracticeguideline |